PecSys: In situ gelling system for optimised nasal drug delivery

Expert Opinion on Drug Delivery

Volumn 6, Issue 5, 2009, Pages 543-552

  Watts, Peter ^a   Smith, Alan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Buprenorphine; Fentanyl; Gel; Modified release; Mucosal; Nasal; Pain; Pectin

Indexed keywords

BUPRENORPHINE; CARBOMER; CHITOSAN; FENTANYL CITRATE; GELLAN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; MACROGOL; NASALFENT; PECTIN; PLACEBO; POLOXAMER; POLYMER; UNCLASSIFIED DRUG;

ANALGESIA; AREA UNDER THE CURVE; BUNIONECTOMY; CHRONIC PAIN; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DOSE TITRATION; DRUG FORMULARY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IN VITRO STUDY; INTRANASAL DRUG ADMINISTRATION; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MUCOSA; NONHUMAN; PAIN; REVIEW; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRANASAL; ANIMALS; BUPRENORPHINE; CLINICAL TRIALS AS TOPIC; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; FENTANYL; GELS; HUMANS; PECTINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 67649229310     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902939135     Document Type: Review

References (75)

1. Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24 •• Formulation-focused review of nasal delivery. (Pubitemid 46756063)
2. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release 2003;87:187-198 • Concise review of nasal delivery. (Pubitemid 36255456)
3. Rapoport A, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache 2006;46 Suppl 4:S192-201 (Pubitemid 44656904)
4. Nascobal (cyanocobalamin USP) nasal spray. Available from: www.nascobal.com/product website [Last accessed 26 January 2009]
5. Christensen KS, Cohen AE, Mermelstein FH, et al. The analgesic efficacy and safety of a novel intranasal morphine formulation (morphine plus chitosan), immediate release oral morphine, intravenous morphine, and placebo in a postsurgical dental pain model. Anesth Analg 2008;107:2018-2024
6. Britannia Pharmaceuticals, Apomorphine nasal. Available from: www.britannia-pharm.co.uk/partnerships.shtml#Apo-nasal%20PD [Last accessed 26 January 2009]
7. Ikano Therapeutics Inc. Midazolam. Available from: http://www.intranasal. com/midazolam.html [Last accessed 23 March 2009]
8. Archimedes Pharma Announces First Positive Phase III Clinical Trial Results for NasalFent. Available from: www.archimedespharma.com/newseventsNews- 091008.html [Last accessed 30 March 2009]
9. Vernalis R&D Centre, Post operative pain: V1003. Available from: www.vernalis.com/ver/rdc2/pain/v1003/ [Last accessed 26 January 2009]
10. Leary AC, Dowling M, Cussen K, et al. Pharmacokinetics and Pharmacodynamics of Intranasal Insulin Spray (Nasulin™) Administered to Healthy Male Volunteers: Influence of the Nasal Cycle. Journal of Diabetes Science and Technology 2008;2:1054-1060
11. Washington N, Washington C, Wilson CG. Physiological Pharmaceutics: barriers to drug absorption, 2nd edition, Taylor & Francis, London, 2001; p. 211
12. Soane RJ, Frier M, Perkins AC, et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999;178:55-65 (Pubitemid 29074407)
13. Cheng YH, Dyer AM, Jabbal-Gill I, et al. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. Eur J Pharm Sci 2005;26:9-15 (Pubitemid 41097256)
14. FluMist® nasal flu vaccine spray for children and adults. Available from: www.flumist.com [Last accessed 26 January 2009]
15. Mcneela EA, Jabbal-Gill I, Illum L, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004;22:909-914 (Pubitemid 38221084)
16. Klas SD, Petrie CR, Warwood SJ, et al. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine 2008;26:5494-5502
17. DelSite Files IND for Nasal Powder H5N1 (Bird Flu) Influenza Vaccine. Available from: www.reuters.com/article/pressRelease/idUS170526+20-Aug- 2008+GNW20080820 [Last accessed 26 January 2009]
18. Rennie P, Bowtell P, Hull D, et al. Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection. Respir Res 2007; 8: 38
19. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-281 (Pubitemid 20187930)
20. Akela Pharma, products, Fentanyl TAIFUN®. Available from: www.akelapharma.com/products.html [Last accessed 26 January 2009]
21. Alexza pharmaceuticals product pipeline. Available from: www.alexza.com/products [Last accessed 26 January 2009]
22. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007;23:223-233 (Pubitemid 46191684)
23. Darwish M, Kirby M, Robertson P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007;47:343-350 (Pubitemid 46294716)
24. Lennernäs B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2004;59:249-253 (Pubitemid 40208864)
25. Hartrick CT, Bourne MH, Gargiulo K, et al. Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine intravenous patient-controlled analgesia. Reg Anesth Pain Med 2006;31:546-554 (Pubitemid 44810090)
26. Tombs M, Harding SE. An Introduction to Polysaccharide Biotechnology, Taylor & Francis, London, 1998; p. 47-94
27. Food Chemicals Codex, Fifth Edition. National Academies Press, Washington, 2003; 321-324
28. United States Pharmacopeia 30 / National Formulary 25. US Pharmacopeial Convention, Rockville, MD, 2006; 2869
29. Rolin C. Chapter 10. Pectin. In: Whistler RL and BeMiller JN, Editors, Industrial Gums. Academic Press, New York, 1993; 257-293
30. May CD. Industrial Pectins: Sources, production and applications. Carbohydrate Polymers 1990;12:79-99
31. Carrington Laboratories Inc. Aloe pectins. US5929051; 1999
32. West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited. Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces. US6432440; 2002 •• Patent covering PecSys technology.
33. Eichner H, Behbehani AA, Hochstrasser K. Diagnostic value of nasal secretions, current state: normal values. 1. Laryngol Rhinol Otol (Stuttg) 1983;62:561-565
34. Lorin MI, Gaerlan PF, Mandel ID. Quantitative composition of nasal secretions in normal subjects. J Lab Clin Med 1972;80:275-281
35. Guyton AC, Hall JE. Guyton & Hall, Textbook of medical physiology, tenth edition, W.B. Saunders, Philadelphia, 2000;899-915
36. Davis GA, Rudy AC, Archer S, et al. Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis. Pharmacotherapy 2004;24:26-32 (Pubitemid 38056249)
37. Davis GA, Rudy AC, Archer SM, et al. Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis. Clin Drug Investig 2004;24:633-639 (Pubitemid 39577343)
38. Greiff L, Andresson M, Svensson J, et al. Absorption across the nasal airway mucosa in house dust mite perennial allergic rhinitis. Clin Physiol Funct Imaging 2002;22:55-57 (Pubitemid 34477310)
39. Wu J, Wei W, Wang LY, et al. A thermosensitive hydrogel based on quarternized chitosan and poly(ethylene glycol) for nasal drug delivery system. Biomaterials 2007;28:2220-2232 (Pubitemid 46216447)
40. Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RSR. Thermoreversible mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 2006; 7: Article 67 (http://www.aapspharmscitech.org) (Pubitemid 44270121)
41. Cao SL, Ren XW, Zhang QZ, et al. In-situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int J Pharm 2009;365:109-115
42. Axelos MAV, Thibault J-F. Chapter 6. The chemistry of low methoxyl pectin gelation. In: The Chemistry and Technology of Pectin. Walter RH, Editor, Academic Press, San Diego, 1991; 109-118
43. Thakur BR, Singh RK, Hanada AK. Chemistry and uses of pectin - a review. Crit Rev Food Sci Nutr 1997;37:47-73
44. Pietrusko RG. Drug therapy reviews: pharmacotherapy of diarrhea. Am J Hosp Pharm 1979; 36: 757-767 (Pubitemid 9199580)
45. Di Lorenzo C, Williams CM, Hajnal F, Valenzuela JE. Pectin delays gastric emptying and increases satiety in obese subjects. Gastroenterology 1998;95:1211-1215
46. Martindale, Thirty-fifth edition. Sweetman SC, Editor, Pharmaceutical Press, London, 2007; 1948
47. Handbook of Pharmaceutical Excipients, Fifth Edition. Rowe RC, Sheskey PJ and Owen SC, Editors, Pharmaceutical Press, London and American Pharmacists Association, Washington, 2006; 507-508
48. Itoh K, Hirayama T, Takahashi A, et al. In situ gelling pectin formulations for oral drug delivery at high gastric pH. Int J Pharm 2007;335:90-96
49. Badve SS, Sher P, Korde A, Pawar AP. Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. Eur J Pharm Biopharm 2007;65:85-93 (Pubitemid 44827695)
50. Sriamornsak P, Thirawong N, Weerapol Y, et al. Swelling and erosion of pectin matrix tablets and their impact on drug release behaviour. Eur J Pharm Biopharm 2007;67:211-219 (Pubitemid 46991322)
51. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 2005;57:1692-1712 (Pubitemid 41444256)
52. Charlton ST, Davis SS, Illum L. Evaluation of bioadhesive polymers as delivery systems for nose to brain delivery: in vitro characterisation studies. J Control Release 2007;118:225-234 (Pubitemid 46343671)
53. Charlton S, Jones NS, Davis SS, Illum L. Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device. Eur J Pharm Sci 2007;30:295-302 (Pubitemid 46299032)
54. DelSite Biotechnologies, Inc., Technology, GelSite® polymer. Available from: www.delsitebiotechnologies.com/newfiles/gelsite.html [Last accessed 26 January 2009]
55. DelSite Biotechnologies, Inc., Technology, GelVac™ Intranasal Powder Vaccine Delivery System. Available from: www.delsitebiotechnologies.com/ newfiles/gelvac.html [Last accessed 26 January 2009]
56. IPPA, International Pectin Producers Association, Safety and legal status of pectins. Available from: www.ippa.info/safety.htm [Last accessed 26 January 2009]
57. Stable Microsystems, Texture analysis. Available from: www.stablemicrosystems. com [Last accessed 26 January 2009]
58. Leitner VM, Guggi D, Krauland AH, Bernkop-Schnürch A. Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system. J Control Rel 2004; 100: 87-95 (Pubitemid 39445988)
59. Moksnes K, Fredheim O, Klepstad P, et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 2008; 64: 497-502
60. Davies G, Fisher A, Knight A, Love R. Nasalfent, a novel intranasal formulation of fentanyl, is well-tolerated during treatment of breakthrough cancer pain. Proceedings of 10th Congress of the European Association for Palliative Care, Budapest, 2007; oral abstract 25
61. Davies G, Fisher A, Knight A, Love R. Nasalfent, a novel intranasal formulation of fentanyl, is rapidly effective and well-tolerated during treatment of breakthrough cancer pain, Proceedings of 10th Congress of the European Association for Palliative Care, Budapest, 2007; poster abstract 711
62. Davies G, Fisher A, Knight A, Love R. Rapid pain relief with fentanyl citrate nasal spray (Nasalfent) in cancer patients with breakthrough pain, Proceedings of 10th Congress of the European Association for Palliative Care, Budapest, 2007; poster abstract 712
63. Danbiosyst UK. Systemic drug delivery compositions comprising a cationic substance. US5554388; 1996
64. Archimedes Development. Vaccine compositions including chitosan for intranasal administration and use thereof. US7323183; 2008
65. Archimedes Pharma Limited, Nasal technology, ChiSys®. Available from: www.archimedespharma.com/productArchiDevChiSys.html [Last accessed 26 January 2009]
66. Bentley Pharmaceuticals Inc. Pharmaceutical compositions and methods for peptide treatment. US7244703; 2007
67. CPEX Pharmaceuticals Inc, CPE-215® Permeation Enhancement Technology. Available from: www.cpexpharm.com/company.htm [Last accessed 26 January 2009]
68. The UAB, Research Foundation. Absorption enhancers for drug administration. US5661130; 1997
69. Aegis Therapeutics, Inc. Intravail® Technology. Available from: http://aegisthera.com/technology.html [Last accessed 26 January 2009]
70. Britannia Pharmaceuticals Limited. Powdered compositions of sensitive active materials in at least partially amorphous state. WO2005084646; 2005
71. Britannia Pharmaceuticals, Apomorphine nasal. Available from: www.britannia-pharm.co.uk/partnerships.shtml#Lyonase%20delivery%20description [Last accessed 26 January 2009]
72. Thiomatrix, Drug delivery technologies. Available from: www.thiomatrix.com/technology/technology.html [Last accessed 26 January 2009]
73. Bernkop-schnürch A. Muco-adhesive polymers, use thereof and method for producing the same. EP1126881; 2004
74. Nastech Pharmaceutical Company, Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity. US7157426; 2007
75. Nastech Pharmaceutical Company, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone. US7244709; 2007